Dear Dr. Caltabiano:

Please refer to your supplemental biologics license application (sBLA), dated November 12, 2021, received November 12, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for Jemperli (dostarlimab-gxly) Injection.

This Prior Approval supplemental biologics application provides for revisions to the Clinical Pharmacology section, Pharmacokinetics subsection (12.3) of the Jemperli Prescribing Information to update sample size for patients with endometrial cancer from the population PK analysis report dated November 19, 2020, submitted under BLA 761223.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling text for the Prescribing Information, and Medication Guide, and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
The SPL will be accessible via publicly available labeling repositories. Also, within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Amy Tilley, Regulatory Project Manager, at amy.tilley@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Laleh Amiri-Kordestani, MD
Director
Division of Oncology 1
Office of Oncologic Diseases
Center for Drug Evaluation & Research

ENCLOSURES:
- Content of Labeling
  - Prescribing Information
  - Medication Guide

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LALEH AMIRI KORDESTANI
04/28/2022 01:57:09 PM